Literature DB >> 16799601

Classification and diagnosis of mastocytosis: current status.

D D Metcalfe1.   

Abstract

Mastocytosis is a disease characterized by an abnormal increase in mast cells. Manifestations of the disease are provoked in large part by the resultant increase in mast cell-derived mediators, which have a variety of local and systemic effects. Mastocytosis is variable in respect to the organ systems involved, clinical manifestations, and association with hematologic diseases. This has suggested the need for an improved classification scheme to allow assessment of prognosis and therapy. The heterogeneity of the disease patterns in mastocytosis strongly suggests that more than one biologic lesion may occur in the developmental sequence that leads to placement of mature mast cells in tissues.

Entities:  

Mesh:

Year:  1991        PMID: 16799601     DOI: 10.1111/1523-1747.ep12468882

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

Review 1.  Mastocytosis and disorders of mast cell proliferation.

Authors:  Joanne K Simpson; Dean D Metcalfe
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

2.  Mastocytosis: the great masquerader.

Authors:  James S W Kong; Suzanne Teuber; Rosemary Hallett; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2006-02       Impact factor: 8.667

Review 3.  The Role of KIT Mutations in Anaphylaxis.

Authors:  Elise Coulson; Sherry Zhou; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2019-04-26       Impact factor: 4.806

4.  CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells.

Authors:  Mathias Schneeweiss-Gleixner; Yüksel Filik; Gabriele Stefanzl; Daniela Berger; Irina Sadovnik; Karin Bauer; Dubravka Smiljkovic; Gregor Eisenwort; Nadine Witzeneder; Georg Greiner; Gregor Hoermann; Ana-Iris Schiefer; Juliana Schwaab; Mohamad Jawhar; Andreas Reiter; Wolfgang R Sperr; Michel Arock; Peter Valent; Karoline V Gleixner
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

Review 5.  Contemporary challenges in mastocytosis.

Authors:  H David Pettigrew; Suzanne S Teuber; James S Kong; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 6.  European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.

Authors:  Peter Valent; Michel Arock; Patrizia Bonadonna; Knut Brockow; Sigurd Broesby-Olsen; Luis Escribano; Karoline V Gleixner; Clive Grattan; Emir Hadzijusufovic; Hans Hägglund; Olivier Hermine; Hans-Peter Horny; Hanneke C Kluin-Nelemans; Marcus Maurer; Marek Niedoszytko; Boguslaw Nedoszytko; Gunnar Nilsson; Hanneke N G Oude-Elberink; Alberto Orfao; Deepti Radia; Andreas Reiter; Frank Siebenhaar; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Jaap J VanDoormaal; Judit Várkonyi; Selim Yavuz; Karin Hartmann
Journal:  Wien Klin Wochenschr       Date:  2012-11-20       Impact factor: 1.704

7.  Mastocytosis presenting as cardiac emergency.

Authors:  Erminia Ridolo; Massimo Triggiani; Marcello Montagni; Elisa Olivieri; Andrea Ticinesi; Antonio Nouvenne; Diomira Magliacane; Gennaro de Crescenzo; Tiziana Meschi
Journal:  Intern Emerg Med       Date:  2013-10-18       Impact factor: 3.397

8.  Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.

Authors:  Susanne Gamperl; Gabriele Stefanzl; Barbara Peter; Dubravka Smiljkovic; Karin Bauer; Michael Willmann; Peter Valent; Emir Hadzijusufovic
Journal:  Vet Comp Oncol       Date:  2019-08-13       Impact factor: 2.613

Review 9.  Clinical challenge for gastroenterologists-Gastrointestinal manifestations of systemic mastocytosis: A comprehensive review.

Authors:  Alessandra Elvevi; Elena Maria Elli; Martina Lucà; Miki Scaravaglio; Fabio Pagni; Stefano Ceola; Laura Ratti; Pietro Invernizzi; Sara Massironi
Journal:  World J Gastroenterol       Date:  2022-08-07       Impact factor: 5.374

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.